California-based Kadenwood announced on Thursday, August 20, that it would buy EcoGen Laboratories as it looks to tap into rising demand for hemp-derived cannabidiol (CBD) products, while creating an integrated supplier worth about US$250 million.
CBD, a derivative of the cannabis plant, is believed to ease anxiety and other ills without the high of its close cousin, marijuana. The product is legally allowed to be sold throughout the United States and can be infused with food and drinks.
The deal will help Kadenwood, which grows its own hemp and sells packaged products derived from it, gain access to EcoGen’s industrial-scale capacity for making ingredients and extracts.
“For us, it was the right time to unite the two very strong brands in the space. Both that are individually focused on different segments of the market – consumer packaged goods and the ingredient space,” Kadenwood Chief Commercial Officer Garrett Bain told Reuters.
Featured News
Prime Therapeutics Found in Violation of Antitrust Laws, Arbitrator Rules
Jan 23, 2025 by
CPI
Honda and Nissan Face Challenges in China Amid Potential Merger
Jan 23, 2025 by
CPI
Trump Criticizes EU’s Tech Crackdown, Calls It ‘A Form of Taxation’
Jan 23, 2025 by
CPI
Meta Faces Fresh Allegations of EU Law Breaches in Subscription Service Rollout
Jan 23, 2025 by
CPI
European Commission Investigates Crypto Rules for Cross-Border Stablecoins
Jan 23, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon